Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
53 hedge funds and large institutions have $9.28M invested in Carisma Therapeutics in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 20 closing their positions.
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
4% more funds holding
Funds holding: 51 → 53 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.37% less ownership
Funds ownership: 21.08% → 14.7% (-6.4%)
52% less capital invested
Capital invested by funds: $19.3M → $9.28M (-$10M)
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$347K |
| 2 |
Millennium Management
New York
|
+$239K |
| 3 |
Jane Street
New York
|
+$238K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$113K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.53M |
| 2 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$910K |
| 3 |
State Street
Boston,
Massachusetts
|
-$656K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$366K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$277K |
CARM Hedge Fund Activity: Q2 2024 in Review
53 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2024, worth a combined $9.28M — down 52% from $19.3M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CARM positions and 20 closed out — a net gain of 2 holders — while 7 added to existing stakes and 16 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $347K. The largest seller was BlackRock, cutting an estimated $1.53M.
- 53 institutional investors held Carisma Therapeutics (CARM) as of Q2 2024, up from 51 in Q1 2024.
- Funds reported $9.28M of Carisma Therapeutics stock for Q2 2024, down 52% quarter-over-quarter.
- 22 funds opened new Carisma Therapeutics positions in Q2 2024 and 20 closed out, a net change of +2 holders.
- The largest Carisma Therapeutics buyer in Q2 2024 was Goldman Sachs, an estimated $347K added.
- The largest Carisma Therapeutics seller in Q2 2024 was BlackRock, an estimated $1.53M sold.
Based on aggregated 13F filings for Q2 2024.